Press releases

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA...
Lipum AB (Publ), a clinical stage biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases...
Lipum (publ) announce today that the project “Identifying proteomic biomarkers to predict the course of early RA” has been granted 2,8 MSEK...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA...
An Extraordinay General Meeting (the “EGM”) in Lipum AB (publ), corporate identity number 556813-5999 (“Lipum” or the “Company”)...
Lipum has developed the drug candidate SOL-116 with the aim of treating inflammatory diseases in a new way. This is based on the discovery of a unique...
The Board of Directors of Lipum AB (publ) (“Lipum” or the “Company”) unanimously recommends the shareholders of Lipum not to accept...
Lipum announces that the first patient with rheumatoid arthritis (RA) has been enrolled and dosed with SOL-116 or placebo in the ongoing phase I clinical...
Lipum AB´s (publ) (“Lipum”) main owner Flerie Invest AB (“Flerie”) announced on 1 March 2024 that it has acquired an additional...

Investor relations